Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNUS Extension Study of Ianalumab in Sjogren's Syndrome
jRCT2041240054Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of ianalumab in Sjögren's syndrome (4 arms), sponsored by Novartis. Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events. Started Dec 2023; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2041240054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240054.